Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics
Status:
Completed
Trial end date:
2018-05-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is:
- To investigate CYP2C9 inhibition by BIA 5-1058 through the assessment of its effect on
the Pharmacokinetic (PK) of S-warfarin, a substrate of CYP2C9.
- To assess the effect of warfarin on the PK of BIA 5-1058.